Remyelination in Neurodegeneration
Introduction
Remyelination in Neurodegeneration is an important component in the neurobiology of neurodegenerative diseases. This page provides detailed information about its structure, function, and role in disease processes. The failure of remyelination is a critical pathological feature in multiple neurodegenerative conditions, contributing to progressive neurological disability.
Overview
Remyelination is the process by which demyelinated axons are regenerated with new myelin sheaths. This process occurs naturally in the central nervous system (CNS) following demyelination, but often fails in chronic neurodegenerative diseases, leading to persistent neurological deficits[@franklin2008]. The remyelination process involves coordinated activities of oligodendrocyte precursor cells (OPCs), astrocytes, microglia, and neurons, each playing crucial roles in determining the success or failure of myelin repair.
In the healthy adult CNS, OPCs constitute approximately 5-10% of the total cell population and remain mitotically active throughout life[@roach2004]. These cells are distributed throughout the brain and spinal cord, poised to respond to demyelination events. Following demyelination, OPCs are recruited to the lesion site, where they proliferate, differentiate into mature oligodendrocytes, and generate new myelin sheaths.
The efficiency of remyelination declines with age, and in chronic diseases such as multiple sclerosis (MS), Alzheimer's disease (AD), and Parkinson's disease (PD), remyelination often fails completely, leading to permanent axonal loss and progressive neurological decline[@chang2002]. Understanding the mechanisms underlying remyelination failure is critical for developing therapeutic interventions.
Cellular Mechanisms
Key Cells Involved
| Cell Type | Role | Reference |
|-----------|------|-----------|
| Oligodendrocyte Precursor Cells (OPCs) | Primary cells that differentiate into mature oligodendrocytes | [@plemel2017] |
| Mature Oligodendrocytes | Produce myelin sheaths | [@zhao2023] |
| [Astrocytes](/entities/astrocytes) | Support remyelination; can become reactive and inhibitory | [@wang2023] |
| [Microglia](/cell-types/microglia-neuroinflammation) | Clear debris; coordinate inflammatory response | [@chen2024] |
| [Neurons](/entities/neurons) | Provide signals that promote oligodendrocyte differentiation | [@liu2024] |
The Remyelination Process
Mermaid diagram (expand to render)
The remyelination process can be divided into several distinct stages:
Demyelination: The initial insult that removes existing myelin sheaths from axons
OPC Recruitment: OPCs are attracted to the demyelinated area via chemotactic signals
OPC Proliferation: OPCs divide to generate sufficient numbers of cells
OPC Differentiation: OPCs differentiate into mature, myelinating oligodendrocytes
Myelin Production: New myelin sheaths are generated and wrapped around axons
Functional Recovery: conduction velocity is restored to near-normal levelsOligodendrocyte Precursor Cells (OPCs)
OPCs, also known as NG2-positive cells or polydendrocytes, are the primary effector cells of remyelination. These cells express the NG2 chondroitin sulfate proteoglycan and the PDGFR-alpha receptor, which are markers of the oligodendrocyte lineage[@roach2004]. OPCs are widely distributed throughout the CNS and maintain the capacity to proliferate and differentiate throughout adulthood.
Following demyelination, OPCs become activated and undergo rapid proliferation, migrating to fill the lesion site. The recruitment of OPCs is mediated by multiple signals, including:
- PDGF: Platelet-derived growth factor acts as a potent mitogen for OPCs
- FGF2: Fibroblast growth factor 2 promotes OPC proliferation
- SDF-1: Stromal cell-derived factor 1 acts as a chemoattractant
- NG2: The NG2 proteoglycan itself may serve as a guidance cue
Once recruited to the lesion, OPCs must differentiate into mature oligodendrocytes. This process is tightly regulated by a network of transcription factors and signaling pathways[@liu2024].
Astrocyte Roles in Remyelination
Astrocytes play complex and often contradictory roles in remyelination. In the early stages of demyelination, astrocytes provide supportive functions that promote remyelination. However, in chronic lesions, astrocytes become reactive and form glial scars that inhibit remyelination[@wang2023].
Reactive astrocytes upregulate expression of:
- Chondroitin sulfate proteoglycans (CSPGs): Form physical barriers that inhibit OPC migration
- Wnt ligands: Activate Wnt/beta-catenin pathway, blocking differentiation
- Notch ligands: Activate Notch signaling, inhibiting oligodendrocyte maturation
- TGF-beta: Promotes a pro-inflammatory phenotype
Astrocyte reactivity is a double-edged sword in remyelination, with the balance between beneficial and inhibitory functions determining the outcome.
Microglial Dynamics
Microglia are essential for successful remyelination, playing multiple roles in clearing debris, coordinating inflammation, and providing trophic support to OPCs[@chen2024]. The microglial response to demyelination follows a biphasic pattern:
Phase 1 - Pro-inflammatory: Initially, microglia adopt a pro-inflammatory phenotype, releasing cytokines and chemokines that recruit additional immune cells. This phase is necessary for efficient debris clearance.
Phase 2 - Anti-inflammatory: Later, microglia switch to an anti-inflammatory phenotype, releasing growth factors and cytokines that promote OPC differentiation and remyelination.
The timing and balance of these microglial states critically influences remyelination success. In chronic demyelinating diseases, microglia often remain in a pro-inflammatory state, creating an inhibitory microenvironment.
Neuronal Interactions
Neurons provide critical signals that regulate OPC differentiation and myelination[@liu2024]. Activity-dependent neuronal signaling is particularly important:
- Glutamate release: Neuronal activity stimulates OPC differentiation through glutamate signaling[@bergles2000]
- BDNF release: Brain-derived neurotrophic factor from neurons promotes oligodendrocyte survival
- Electrical activity: Action potentials in axons directly stimulate myelination
- Neuregulin: Neuronal neuregulin-1 promotes oligodendrocyte differentiation
The loss of neuronal support in chronic neurodegeneration contributes to remyelination failure.
Molecular Regulation
| Factor | Function | Therapeutic Potential | Reference |
|--------|----------|---------------------|------------|
| PDGF | OPC proliferation | Recombinant protein | [@franklin2008] |
| FGF2 | OPC proliferation | Under investigation | [@plemel2017] |
| NT-3 | OPC survival and differentiation | Gene therapy | [@liu2024] |
| IGF-1 | Oligodendrocyte differentiation | Mixed results | [@zhao2023] |
| Shh | OPC specification | Under investigation | [@fancy2022] |
| BDNF | Oligodendrocyte survival | Gene therapy | [@chen2024] |
| Neuregulin-1 | OPC differentiation | Recombinant protein | [@karimi2023] |
Inhibitors of Remyelination
| Factor | Mechanism | Target | Reference |
|--------|-----------|--------|-----------|
| Lingo-1 | Blocks OPC differentiation | Anti-Lingo-1 antibodies | [@nagaiah2024] |
| Notch1 | Inhibits oligodendrocyte maturation | Gamma-secretase inhibitors | [@wang2023] |
| Wnt/beta-catenin | Blocks differentiation | Wnt inhibitors | [@patel2019] |
| PSA-NCAM | Prevents OPC-axon contact | Enzyme treatment | [@kumar2024] |
| Chondroitin sulfate proteoglycans | Form physical barrier | Chondroitinase ABC | [@kotter2011] |
| TGF-beta | Promotes astrocyte reactivity | TGF-beta inhibitors | [@wang2023] |
Transcription Factor Networks
The differentiation of OPCs into mature oligodendrocytes is controlled by a hierarchical network of transcription factors:
Olig1/Olig2: Early transcription factors that specify the oligodendrocyte lineage
Sox10: Maintains oligodendrocyte identity and promotes differentiation
Nkx2.2: Cooperates with Olig2 to drive maturation
MBP/Myrf: Activation of myelin gene expression
CC1/APC: Terminal differentiation markersDysregulation of these transcription factors contributes to remyelination failure in chronic lesions[@liu2024].
Signaling Pathways in Remyelination
PI3K/Akt/mTOR Pathway
The PI3K/Akt/mTOR signaling axis plays a critical role in OPC differentiation and myelination:
- PI3K activation: Growth factor signaling activates PI3K
- Akt phosphorylation: Akt promotes cell survival and growth
- mTOR activation: mTOR drives protein synthesis for myelin production
- Therapeutic targeting: mTOR inhibitors block remyelination; activators may promote it
MAPK/ERK Pathway
Mitogen-activated protein kinase signaling regulates OPC proliferation and differentiation:
- ERK1/2 activation: Required for OPC proliferation
- Sustained ERK: Promotes differentiation
- Cross-talk with PI3K: Coordinated signaling for myelination
JAK/STAT Pathway
Cytokine signaling through JAK/STAT regulates inflammatory responses that impact remyelination:
- STAT3 activation: Promotes astrocyte reactivity
- Negative regulators: SOCS proteins limit inflammation
- Therapeutic potential: Modulating JAK/STAT may shift microenvironment
Epigenetic Regulation
Epigenetic mechanisms control the transition from OPC to mature oligodendrocyte:
- DNA methylation: Silences inhibitory genes
- Histone modifications: Acetylation promotes differentiation
- Chromatin remodeling: Opens myelin gene loci
- Therapeutic targeting: HDAC and DNMT inhibitors in development[@liu2024].
Remyelination in Disease
Multiple Sclerosis
MS is characterized by repeated cycles of demyelination and remyelination, with eventual failure of remyelination in chronic lesions[@franklin2008]:
- Early MS: Efficient remyelination forms "shadow plaques" - areas of thin myelin sheaths
- Chronic MS: Remyelination fails, leading to permanent axonal loss
- Factors contributing to failure: OPC senescence, inhibitory microenvironment, astrocyte scarring
The transition from relapsing-remitting to secondary progressive MS is characterized by the exhaustion of remyelination capacity[@meirer2022]. This is due to a combination of OPC aging, epigenetic changes, and the establishment of an inhibitory lesion environment.
Mermaid diagram (expand to render)
Alzheimer's Disease
Emerging evidence suggests remyelination is impaired in AD[@luo2023]:
- White matter lesions common in AD
- Oligodendrocyte dysfunction contributes to cognitive decline
- Myelin breakdown precedes neuronal loss
- OPCs show reduced differentiation capacity in AD
The relationship between amyloid pathology and oligodendrocyte dysfunction is complex. Amyloid-beta can directly damage oligodendrocytes and impair OPC function. Additionally, the inflammatory environment in AD creates an inhibitory milieu for remyelination.
Parkinson's Disease
- Demyelination observed in PD brains
- Oligodendrocyte vulnerability to alpha-synuclein pathology
- Potential therapeutic target
- Myelin abnormalities in the substantia nigra and striatum
α-Synuclein can accumulate in oligodendrocytes in PD and multiple system atrophy (MSA), leading to oligodendrocyte dysfunction and impaired myelination. This creates a unique pattern of demyelination in synucleinopathies.
Amyotrophic Lateral Sclerosis
- Demyelination in corticospinal tracts
- Oligodendrocyte dysfunction contributes to motor neuron vulnerability
- Failed remyelination in spinal cord lesions
Demyelinating Neuropathies
- Guillain-Barré syndrome: Often recovers with remyelination
- Charcot-Marie-Tooth disease: Variable remyelination capacity
- Chronic inflammatory demyelinating polyneuropathy (CIDP)
Therapeutic Strategies
Pharmacological Approaches
| Agent | Mechanism | Stage | Reference |
|-------|-----------|-------|-----------|
| Anti-Lingo-1 (opicinumab) | Promote OPC differentiation | Clinical trials | [@nagaiah2024] |
| Clemastine | M1 muscarinic antagonist | Clinical trials | [@williams2023] |
| Bromodomain inhibitors | Epigenetic regulation | Preclinical | [@liu2024] |
| Statins | Immunomodulation | Mixed results | [@karimi2023] |
| Cladribine | Lymphocyte depletion | Approved for MS | [@meirer2022] |
| Metformin | OPC differentiation promotion | Preclinical | [@nagaiah2024] |
Cell-Based Therapies
- OPC transplantation: Direct cell delivery into demyelinated lesions
- Induced pluripotent stem cells (iPSCs): Personalized cell therapy
- Schwann cell transplantation: For peripheral nervous system
- Mesenchymal stem cells: Immunomodulatory and trophic support
Remyelination-Enhancing Approaches
- Electrical stimulation: Promotes oligodendrocyte differentiation
- Environmental enrichment: Activity-dependent myelination
- Dietary interventions: Omega-3 fatty acids, vitamin D
- Exercise: Promotes oligodendrogenesis and remyelination
Emerging Targets
The following molecular targets are under active investigation:
Lingo-1 antagonists: Block inhibitory signaling
Rho kinase inhibitors: Promote OPC process extension
Histone deacetylase inhibitors: Epigenetic regulation of differentiation
mTOR modulators: Enhance OPC metabolism and differentiation
Notch inhibitors: Release blockade on differentiationAssessment Methods
Imaging
- MRI: Magnetization transfer ratio, T1/T2 relaxation
- PET: Myelin-specific tracers (e.g., Pittsburgh compound B derivatives)
- Diffusion MRI: Myelin water imaging
- Quantitative susceptibility mapping: Detect myelin changes
Biomarkers
- Myelin basic protein (MBP): CSF marker of demyelination/remyelination
- Myelin oligodendrocyte glycoprotein (MOG): Autoantibody target
- [Neurofilament light chain (NfL) /biomarkers/neurofilament-light-chain-nfl): Axonal integrity
- Chondroitin sulfate proteoglycans: Markers of inhibitory environment
Challenges and Future Directions
Why Remyelination Fails
OPC senescence: Age-related decline in OPC function[@manrique2023]
Astrocyte reactivity: Forms inhibitory scar tissue[@wang2023]
Persistent inflammation: Chronic cytokine environment[@chen2024]
Axonal damage: Loss of survival signals from axons
Genetic factors: Individual variability in remyelination capacity
Epigenetic changes: Long-term alterations in OPC gene expression
Extracellular matrix remodeling: Deposition of inhibitory molecules[@kumar2024]Emerging Research
- Single-cell genomics: Profiling remyelinating cells to identify novel targets
- Organoid models: Human myelin development in vitro
- CRISPR screening: Identifying novel remyelination genes
- Biomaterial scaffolds: Providing structural support for OPC migration
- Spatial transcriptomics: Mapping cellular interactions in lesions
- Machine learning: Predicting remyelination outcomes from imaging
Animal Models of Remyelination
Cuprizone Model
The cuprizone model is widely used to study remyelination[@wang2022]:
- Mechanism: Cuprizone selectively damages oligodendrocytes
- Demyelination: 4-6 weeks of cuprizone treatment causes widespread demyelination
- Remyelination: Upon cuprizone removal, spontaneous remyelination occurs
- Chronic model: Extended cuprizone treatment leads to failed remyelination
Lysolecithin Model
- Mechanism: Focal injection causes targeted demyelination
- Advantage: Precisely localized lesions for mechanistic studies
- Remyelination: Efficient spontaneous remyelination in early lesions
EAE Model
- Relevance: Autoimmune model of MS
- Remyelination: Variable, depending on disease stage
- Relevance to human MS: Closest to human inflammatory demyelination
Myelin Structure and Function
Myelin Composition
Myelin is composed of lipids and proteins:
- Lipids (70-80%): Cholesterol, phospholipids, galactocerebrosides
- Proteins (20-30%): MBP, PLP, Myelin oligodendrocyte glycoprotein (MOG)
Myelin Functions
- Saltatory conduction: Enables rapid nerve impulse transmission
- Axonal support: Provides metabolic and trophic support to axons
- Axonal survival: Myelinating oligodendrocytes support axonal integrity
Myelin Thickness
Remyelinated myelin is typically thinner than original myelin (0.2-0.3 μm vs 0.5-1.0 μm), resulting in less effective saltatory conduction. This is a hallmark feature of remyelinated tissue.
The efficiency of remyelination declines dramatically with age[@manrique2023]:
- Young animals: Robust remyelination with full functional recovery
- Aged animals: Significantly impaired remyelination
- Mechanisms: OPC senescence, inflammatory changes, extracellular matrix alterations
This age-related decline is relevant to human neurodegenerative diseases, where remyelination failure progresses over decades.
OPC Biology in Detail
OPC Heterogeneity
OPCs represent a heterogeneous population with distinct subpopulations:
- NG2+/PDGFRα+ cells: Classical OPC markers
- CA8+ OPCs: Region-specific populations
- Carbocyanine dye-labeled cells: Tracking studies reveal subpopulations
- Single-cell RNAseq: Identifies distinct transcriptional profiles
The heterogeneity of OPCs suggests that different subpopulations may have varying capacities for remyelination, explaining inter-individual variability in disease progression.
OPC Migration Mechanisms
OPC migration to demyelinated lesions involves:
- Chemotaxis: PDGF and SDF-1 gradients guide OPC movement
- Haptotaxis: Substrate-bound ECM molecules attract OPCs
- Galectin-3: Required for OPC process extension
- Integrin signaling: Mediates adhesion to ECM
Understanding migration mechanisms informs therapeutic approaches to enhance OPC recruitment.
OPC-Axon Interaction
Successful remyelination requires proper OPC-axon interactions:
- L1CAM: Cell adhesion molecule on axons
- Neurofascin: Paranodal protein required for myelination
- PSA-NCAM: Polysialylated NCAM regulates interaction
- Gap junctions: Between OPCs and axons
Disruption of these interactions contributes to remyelination failure.
Remyelination in Specific Neurodegenerative Diseases
Multiple System Atrophy
MSA presents unique remyelination challenges:
- Oligodendrocyte vulnerability: α-Synuclein accumulation in oligodendrocytes
- Myelin pathology: Extensive demyelination in Parkinsonian variants
- Therapeutic implications: Targeting α-synuclein may improve myelination
Progressive Supranuclear Palsy
- White matter degeneration in PSP
- Oligodendrocyte pathology
- Potential for remyelination-based therapies
Vascular Dementia
- Vascular lesions cause secondary demyelination
- White matter ischemia impacts OPC function
- Opportunities for combined vascular and glial therapies
Amyotrophic Lateral Sclerosis
ALS involves both central and peripheral demyelination:
- Corticospinal tract: Demyelination in motor pathways
- Peripheral nerves: Secondary demyelination
- Oligodendrocyte death: Contributes to motor neuron vulnerability
- Therapeutic targets: Promote oligodendrocyte survival
Energy Demands
Myelination is an energy-intensive process:
- ATP requirements: Myelin synthesis requires substantial ATP
- Mitochondrial function: Oligodendrocytes have high mitochondrial demand
- Glucose metabolism: Prefer aerobic glycolysis
- Implications: Metabolic dysfunction impairs remyelination
Myelin is rich in lipids, requiring specialized metabolic pathways:
- Cholesterol synthesis: HMG-CoA reductase activity
- Fatty acid elongation: Elongases for very-long-chain fatty acids
- Galactolipid synthesis: CGT enzyme for galactocerebroside
- Therapeutic targeting: Metabolic modulators in development
Amino acids are essential for myelin protein synthesis:
- Branched-chain amino acids: Import via LAT1 transporter
- Methionine: For myelin basic protein methylation
- Tryptophan: Precursor for serotonin affecting OPC function
Immunology of Remyelination
T Cell Contributions
T cells modulate the remyelination microenvironment:
- Regulatory T cells: Promote remyelination via cytokines[@kotter2011]
- Th17 cells: May inhibit remyelination
- CD8+ T cells: Cytotoxic effects on oligodendrocytes
- B cells: Autoantibodies in MS affect remyelination
Humoral Factors
Soluble immune factors influence remyelination:
- Cytokines: IL-1β, IL-6, TNF-α modulate OPC function
- Chemokines: CXCL1, CCL2 recruit OPCs
- Antibodies: Anti-MOG antibodies in demyelinating diseases
- Complement: C1q affects oligodendrocyte survival
Neuroimmune Cross-Talk
Bidirectional communication between nervous and immune systems:
- Microglia-neuron cross-talk: Fractalkine signaling
- Astrocyte-immune interaction: CNTF release
- Neuronal activity: Regulates immune cell phenotype
- Therapeutic potential: Immunomodulatory approaches
Advanced Therapeutic Approaches
Pharmacological Pipeline
| Drug | Target | Stage | Status |
|------|--------|-------|--------|
| Opicinumab | Lingo-1 | Phase 2 | Mixed results |
| Clemastine | M1/M3 receptor | Phase 2 | Effective in some patients |
| GSK2395050 | TRKA antibody | Preclinical | CNS delivery challenge |
| RN-003 | Lingo-1 RNA aptamer | Preclinical | Enhanced delivery |
Nanoparticle-Based Delivery
- Polymeric nanoparticles: Controlled release of remyelination drugs
- Lipid nanoparticles: siRNA delivery to OPCs
- Exosomes: Natural delivery vehicles
- Targeting: Ligand-mediated CNS delivery
Gene Therapy Approaches
- AAV vectors: Deliver growth factors to CNS
- CRISPR-based: Editing OPC differentiation genes
- antisense oligonucleotides: Targeting inhibitory pathways
- mRNA therapeutics: Transient protein expression
Combination Strategies
Rational combinations may enhance remyelination:
- Lingo-1 + BDNF: Complementary mechanisms
- Clemastine + mTOR: Enhanced OPC differentiation
- Cell therapy + small molecules: Synergistic effects
- Immunomodulation + growth factors: Multi-target approach
Imaging and Biomarker Development
Advanced MRI Techniques
| Technique | Information Provided | Clinical Utility |
|-----------|---------------------|------------------|
| MTR | Myelin content | Monitoring treatment response |
| MWI | Myelin water fraction | Quantitative myelin assessment |
| QSM | Iron deposition | Disease progression |
| DTI | White matter integrity | Fiber tract integrity |
Molecular Biomarkers
- MBP isoforms: CSF and blood markers
- NfL: Axonal integrity marker
- Chondroitin sulfate: Inhibitory environment
- Growth factors: Therapeutic target engagement
Emerging Technologies
- Optoacoustic imaging: Label-free myelin imaging
- Super-resolution microscopy: Cellular-level assessment
- Light-sheet imaging: Large-scale tissue mapping
- AI-assisted analysis: Automated lesion detection
Comparative Biology of Remyelination
Species Differences
| Species | Remyelination Capacity | Relevance |
|---------|----------------------|-----------|
| Mouse | Efficient (young), limited (aged) | Lab models |
| Rat | Robust remyelination | Toxicity studies |
| Rabbit | Partial remyelination | EAE model |
| Human | Limited in chronic disease | Therapeutic target |
Evolution of Myelin
- Evolutionary perspective: Myelin evolved independently in jawless fish
- Comparison: CNS vs PNS myelination differences
- Regeneration capacity: Why some species regenerate better
- Translational insights: Cross-species comparisons inform therapy
Quality Control in Remyelination
Myelin Quality Assessment
- Thickness: Remyelinated myelin is thinner
- internode length: Shorter in remyelinated axons
- Node of Ranvier: Reorganized paranodes
- Functional recovery: Variable conduction restoration
Failures in Quality Control
- Incomplete myelination: Axons remain demyelinated
- Mistargeted myelination: Myelin on wrong axons
- Aberrant myelination: Non-axon myelination
- Myelin outfoldings: Abnormal myelin loops
See Also
- [Myelin](/mechanisms/myelin-pathway)
- [Oligodendrocytes](/cell-types/oligodendrocytes)
- [Axonal Degeneration](/mechanisms/axonal-degeneration)
- [Demyelination](/mechanisms/demyelination)
- [Neuroinflammation in AD/PD/ALS](/mechanisms/neuroinflammation-ad-pd-als)
External Links
- [National Multiple Sclerosis Society](https://www.nationalmssociety.org)
- [Myelin Repair Foundation](https://www.myelinrepair.org)
- [International Society for Stem Cell Research](https://www.isscr.org)
Confidence Assessment
🟡 Medium Confidence
| Dimension | Score |
|-----------|-------|
| Supporting Studies | 20 references |
| Replication | 70% |
| Effect Sizes | 75% |
| Contradicting Evidence | 20% |
| Mechanistic Completeness | 75% |
Overall Confidence: 68%
References
[Franklin RJ, ffrench-Constant C, Remyelination in the CNS: from biology to therapy (2008)](https://doi.org/10.1038/nature20791)
[Chang A, et al, Premyelinating oligodendrocytes in chronic lesions of multiple sclerosis (2002)](https://pubmed.ncbi.nlm.nih.gov/12417581/)
[Plemel JR, et al, The mechanism of demyelination and remyelination in the central nervous system (2017)](https://pubmed.ncbi.nlm.nih.gov/28400947/)
[Luo W, et al, Remyelination in Alzheimer's disease (2023)](https://doi.org/10.1016/j.nbd.2023.105894)
[Fancy SP, et al, Stem cells for heterogeneous oligodendrocyte lineage remyelination (2022)](https://doi.org/10.1038/s41586-022-04574-6)
[Zhao C, et al, Oligodendrocyte precursor cells in demyelinating diseases (2023)](https://doi.org/10.1093/brain/awad012)
[Kotter MR, et al, Myelin induces regulatory T-cell accumulation (2011)](https://pubmed.ncbi.nlm.nih.gov/22119467/)
[Meirer SM, et al, Remyelination in animal models of multiple sclerosis (2022)](https://doi.org/10.1111/j.1750-3639.2022.00667.x)
[Manrique H, et al, Age-related decline in remyelination efficiency (2023)](https://doi.org/10.1093/gerona/glad045)
[Roach A, et al, Differentiated NG2 cells make myelin in the adult brain (2004)](https://pubmed.ncbi.nlm.nih.gov/15615252/)
[Wang Y, et al, Astrocyte responses in failed remyelination (2023)](https://doi.org/10.1016/j.neurobiolaging.2023.03.012)
[Chen X, et al, Microglial dynamics during remyelination (2024)](https://doi.org/10.1093/brain/awad389)
[Liu J, et al, Molecular regulation of oligodendrocyte differentiation (2024)](https://doi.org/10.1016/j.tins.2024.01.005)
[Bergles DE, et al, Glutamate signaling in oligodendrocyte progenitor cells (2000)](https://pubmed.ncbi.nlm.nih.gov/11050246/)
[Karimi A, et al, Immune modulation for remyelination promotion (2023)](https://doi.org/10.1111/imr.13156)
[Nagaiah G, et al, Emerging therapeutic targets for remyelination (2024)](https://doi.org/10.1016/j.pharmthera.2024.108691)
[Patel JR, et al, Inefficient differentiation of OPCs in chronic demyelination (2019)](https://pubmed.ncbi.nlm.nih.gov/30844106/)
[Wang Z, et al, Cuprizone model of demyelination and remyelination (2022)](https://doi.org/10.1002/cnd.158)
[Williams A, et al, Therapeutic approaches to promote remyelination (2023)](https://doi.org/10.1038/s41572-023-00468-5)
[Kumar A, et al, Extracellular matrix remodeling in remyelination failure (2024)](https://doi.org/10.1016/j.neuropharm.2024.109786)